💤 Pregabalin Dose-Titration Simulator

Baseline Starting Dose — 75 mg Twice Daily

Low starting dose limits early sedation while therapy begins.

• 150 mg/day: Starting dose (75 mg twice daily)
• ~6.3 h: Half-life (renal clearance, linear PK)
• ≥90%: Bioavailability (not protein bound)
• ~24–48 h: Time to steady state (after each dose change)

Why start low

Low first dose reduces early dizziness and sedation risk.

Pharmacokinetics

Linear kinetics, renal excretion, minimal drug interactions.

Patient selection

Renal dose adjustment needed for reduced kidney function.

Gradual Up-Titration to Target Dose

Dose increases stepwise toward 150–225 mg twice daily.

• 300–450 mg/day: Target dose range (150–225 mg twice daily)
• 1–2 weeks: Titration window (weekly dose increments)
• 450 mg/day: Max approved dose (FDA fibromyalgia label)
• +150 mg/wk: Common increment (as tolerated)

Titration schedule

Stepwise increases allow tolerance to sedation to build.

Monitoring

Watch for dizziness, somnolence, weight gain, edema.

Discontinuation

Taper gradually over one week to avoid withdrawal.

α2δ Subunit Binding at the Nerve Terminal

Pregabalin binds voltage-gated calcium channel auxiliary subunits.

• α2δ-1 subunit: Binding target (voltage-gated Ca²⁺ channels)
• ↓ Ca²⁺ influx: Channel effect (reduced presynaptic entry)
• Glutamate, substance P: Neurotransmitters reduced (excitatory release)
• Non-opioid: Mechanism class (gabapentinoid, not GABA-mimetic)

Channel binding

Binds auxiliary subunit, not the pore-forming subunit itself.

Downstream effect

Fewer calcium ions trigger vesicle fusion and release.

Central sensitization

Dampened excitatory signaling reduces pain amplification.

Analgesic Benefit and Sedation Rise in Parallel

Higher doses bring more relief but also more sedation.

• Saturating: Relief curve shape (diminishing returns at high dose)
• Sigmoidal: Sedation curve shape (steep rise past ~400 mg/day)
• Dizziness, somnolence: Common side effects (dose-dependent incidence)
• ~15–20%: Discontinuation for AEs (clinical trial data)

Analgesia curve

Pain relief saturates as receptor occupancy approaches maximum.

Sedation curve

Sedation accelerates once dose exceeds tolerability threshold.

Divergence point

Curves separate, defining the useful therapeutic window.

Finding the Balance Point — Net Clinical Benefit

Optimal dose maximizes relief while keeping sedation tolerable.

• ~300–375 mg/day: Typical sweet spot (model-estimated peak net benefit)
• 450 mg/day: Diminishing returns above (sedation outpaces added relief)
• Titrate to effect: Individualization (balance efficacy and tolerability)
• ~40–50%: Responder rate (≥30% pain reduction, trials)

Net benefit score

Relief minus weighted sedation burden defines the optimum.

Too-high doses

Over-sedation without proportional additional pain relief.

Clinical takeaway

Titrate slowly, find each patient's individual sweet spot.

Slow titration to the lowest effective dose maximizes tolerability.